TW202321227A - 環烯類衍生物調節劑、其製備方法和應用 - Google Patents
環烯類衍生物調節劑、其製備方法和應用 Download PDFInfo
- Publication number
- TW202321227A TW202321227A TW111129379A TW111129379A TW202321227A TW 202321227 A TW202321227 A TW 202321227A TW 111129379 A TW111129379 A TW 111129379A TW 111129379 A TW111129379 A TW 111129379A TW 202321227 A TW202321227 A TW 202321227A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- alkoxy
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110892791 | 2021-08-04 | ||
| CN202110892791.3 | 2021-08-04 | ||
| CN202111322097 | 2021-11-09 | ||
| CN202111322097.4 | 2021-11-09 | ||
| CN202210041958.X | 2022-01-14 | ||
| CN202210041958 | 2022-01-14 | ||
| CN202210540040.X | 2022-05-17 | ||
| CN202210540040 | 2022-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202321227A true TW202321227A (zh) | 2023-06-01 |
Family
ID=85155248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111129379A TW202321227A (zh) | 2021-08-04 | 2022-08-04 | 環烯類衍生物調節劑、其製備方法和應用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240360109A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4382525A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529527A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240042624A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117751110A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022321506A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227366A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310400A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024001331A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202321227A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023011539A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20250139383A (ko) * | 2023-02-02 | 2025-09-23 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 시클로알켄계 화합물의 염, 결정형 및 이의 제조 방법과 응용 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2025252201A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏豪森药业集团有限公司 | 一种环烯类衍生物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022742A1 (en) * | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) * | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| EA202191432A1 (ru) * | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| ES3029360T3 (en) * | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| WO2021219019A1 (en) * | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023538408A (ja) * | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Glp-1r作動薬としての化合物 |
| JP7812052B2 (ja) * | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| CN114805336B (zh) * | 2021-01-20 | 2026-04-14 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
-
2022
- 2022-08-03 US US18/293,637 patent/US20240360109A1/en active Pending
- 2022-08-03 AU AU2022321506A patent/AU2022321506A1/en active Pending
- 2022-08-03 CN CN202280053790.2A patent/CN117751110A/zh active Pending
- 2022-08-03 IL IL310400A patent/IL310400A/en unknown
- 2022-08-03 CA CA3227366A patent/CA3227366A1/en active Pending
- 2022-08-03 EP EP22852251.2A patent/EP4382525A4/en active Pending
- 2022-08-03 MX MX2024001331A patent/MX2024001331A/es unknown
- 2022-08-03 KR KR1020247006472A patent/KR20240042624A/ko active Pending
- 2022-08-03 JP JP2024506443A patent/JP2024529527A/ja active Pending
- 2022-08-03 WO PCT/CN2022/110017 patent/WO2023011539A1/zh not_active Ceased
- 2022-08-04 TW TW111129379A patent/TW202321227A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024001331A (es) | 2024-04-19 |
| WO2023011539A1 (zh) | 2023-02-09 |
| US20240360109A1 (en) | 2024-10-31 |
| IL310400A (en) | 2024-03-01 |
| KR20240042624A (ko) | 2024-04-02 |
| CN117751110A (zh) | 2024-03-22 |
| EP4382525A1 (en) | 2024-06-12 |
| AU2022321506A1 (en) | 2024-02-01 |
| EP4382525A4 (en) | 2025-07-16 |
| JP2024529527A (ja) | 2024-08-06 |
| CA3227366A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117751110A (zh) | 环烯类衍生物调节剂、其制备方法和应用 | |
| CN115244056B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN113816948B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| TW202304440A (zh) | 多環類衍生物調節劑、其製備方法和應用 | |
| CN109983007B (zh) | 酰胺类衍生物抑制剂及其制备方法和应用 | |
| JP5683489B2 (ja) | ピペリジン含有化合物およびその用途 | |
| CN111107848B (zh) | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 | |
| WO2022007979A1 (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN114585622A (zh) | 作为nsd2抑制剂和抗癌剂的哌啶基-甲基-嘌呤胺 | |
| ES2929977T3 (es) | Moduladores del receptor cannabinoide | |
| CN105518008B (zh) | 氨基吡喃环衍生物及其组合物和应用 | |
| CN113801111B (zh) | 联苯类衍生物抑制剂及其制备方法和应用 | |
| WO2014151936A9 (en) | Octahydropyrrolopyrroles, their preparation and use | |
| TWI800489B (zh) | Fgfr4抑制劑及其製備方法和應用 | |
| WO2021244634A1 (zh) | 咪唑并吡啶类化合物及其用途 | |
| CN113166135A (zh) | 苯并噻吩类衍生物调节剂、其制备方法和应用 | |
| CN117986264A (zh) | 苯并含氮多环类衍生物调节剂及其制备方法和应用 | |
| CN118420603A (zh) | 一种环烯类化合物的氨丁三醇盐晶型及其制备方法和用途 | |
| WO2024160271A1 (zh) | 一种环烯类化合物的盐、晶型及其制备方法和应用 | |
| CN119431369A (zh) | 含氮杂芳环类衍生物调节剂、其制备方法和应用 | |
| TW202128693A (zh) | 含吡唑多環類衍生物抑制劑、其製備方法和應用 | |
| CN117986262A (zh) | 稠合二环类化合物、其制备方法及其在医药上的应用 | |
| WO2025261454A1 (zh) | 一种含氮大环化合物衍生物调节剂及其制备方法和应用 | |
| WO2021249417A1 (zh) | 杂环化合物及其衍生物 | |
| EA052008B1 (ru) | Регулятор на основе циклоалкенового производного, способ его получения и его применение |